Karl-Josef Langen1,2,3, Norbert Galldiks1,4,5. 1. Institute of Neuroscience and Medicine (INM-3, INM-4) Forschungszentrum Jülich, Jülich. 2. Department of Nuclear Medicine, RWTH Aachen University Clinic, Aachen. 3. JARA - Jülich Aachen Research Alliance, Jülich. 4. Department of Neurology, University of Cologne, Cologne. 5. Center of Integrated Oncology (CIO), Universities of Cologne and Bonn, Bonn, Germany.
Abstract
PURPOSE OF REVIEW: The aim of this study was to give an update on the emerging role of PET using radiolabelled amino acids in the diagnostic workup and management of patients with cerebral gliomas and brain metastases. RECENT FINDINGS: Numerous studies have demonstrated the potential of PET using radiolabelled amino acids for differential diagnosis of brain tumours, delineation of tumour extent for treatment planning and biopsy guidance, differentiation between tumour progression and recurrence versus treatment-related changes, and for monitoring of therapy. The Response Assessment in Neuro-Oncology (RANO) working group - an international effort to develop new standardized response criteria for clinical trials in brain tumours - has recently recommended the use of amino acid PET imaging for brain tumour management in addition to MRI at every stage of disease. With the introduction of F-18 labelled amino acids, a broader clinical application has become possible, but is still hampered by the lack of regulatory approval and of reimbursement in many countries. SUMMARY: PET using radiolabelled amino acids is a rapidly evolving method that can significantly enhance the diagnostic value of MRI in brain tumours. Current developments suggest that this imaging technique will become an indispensable tool in neuro-oncological centres in the near future.
PURPOSE OF REVIEW: The aim of this study was to give an update on the emerging role of PET using radiolabelled amino acids in the diagnostic workup and management of patients with cerebral gliomas and brain metastases. RECENT FINDINGS: Numerous studies have demonstrated the potential of PET using radiolabelled amino acids for differential diagnosis of brain tumours, delineation of tumour extent for treatment planning and biopsy guidance, differentiation between tumour progression and recurrence versus treatment-related changes, and for monitoring of therapy. The Response Assessment in Neuro-Oncology (RANO) working group - an international effort to develop new standardized response criteria for clinical trials in brain tumours - has recently recommended the use of amino acid PET imaging for brain tumour management in addition to MRI at every stage of disease. With the introduction of F-18 labelled amino acids, a broader clinical application has become possible, but is still hampered by the lack of regulatory approval and of reimbursement in many countries. SUMMARY: PET using radiolabelled amino acids is a rapidly evolving method that can significantly enhance the diagnostic value of MRI in brain tumours. Current developments suggest that this imaging technique will become an indispensable tool in neuro-oncological centres in the near future.
Authors: Norbert Galldiks; Karl-Josef Langen; Nathalie L Albert; Marc Chamberlain; Riccardo Soffietti; Michelle M Kim; Ian Law; Emilie Le Rhun; Susan Chang; Julian Schwarting; Stephanie E Combs; Matthias Preusser; Peter Forsyth; Whitney Pope; Michael Weller; Jörg C Tonn Journal: Neuro Oncol Date: 2019-05-06 Impact factor: 12.300
Authors: Norbert Galldiks; Martin Kocher; Garry Ceccon; Jan-Michael Werner; Anna Brunn; Martina Deckert; Whitney B Pope; Riccardo Soffietti; Emilie Le Rhun; Michael Weller; Jörg C Tonn; Gereon R Fink; Karl-Josef Langen Journal: Neuro Oncol Date: 2020-01-11 Impact factor: 12.300
Authors: Robin Grant; Therese Dowswell; Eve Tomlinson; Paul M Brennan; Fiona M Walter; Yoav Ben-Shlomo; David William Hunt; Helen Bulbeck; Ashleigh Kernohan; Tomos Robinson; Theresa A Lawrie Journal: Cochrane Database Syst Rev Date: 2020-09-04
Authors: Adrien Holzgreve; Dennis Pötter; Matthias Brendel; Michael Orth; Lorraine Weidner; Lukas Gold; Maximilian A Kirchner; Laura M Bartos; Lena M Unterrainer; Marcus Unterrainer; Katja Steiger; Louisa von Baumgarten; Maximilian Niyazi; Claus Belka; Peter Bartenstein; Markus J Riemenschneider; Kirsten Lauber; Nathalie L Albert Journal: Biomedicines Date: 2022-03-22
Authors: Matthew L Scarpelli; Debbie R Healey; Shwetal Mehta; Vikram D Kodibagkar; Christopher C Quarles Journal: Sci Rep Date: 2020-10-14 Impact factor: 4.379